Dade Behring launches homocysteine assay in Europe:
This article was originally published in Clinica
Executive Summary
Dade Behring has introduced for sale in Europe a homocysteine assay for determining a patient's risk of heart attack and stroke. The assay, which is manufactured by Dade's marketing partner Axis-Shield, is designed for use on the company's BNII and BN ProSpec systems. Up to 47% of patients with symptoms of cardiovascular disease show elevated levels of homocysteine, the Deerfield, Illinois firm said. The company added that it may also run the homocysteine test in conjunction with its CardioPhase hsCRP, cholesterol, lipids, Apo A1/Apo B, Lp(a), and microalbuminuria tests. The cardiovascular risk assessment panel is run in both routine and specialised laboratories.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.